Security key
33749P408
Entero Therapeutics, Inc. - Common stock, par value $0.0001 per share (ENTO)
CUSIP: 33749P408
Q3 2024 13F Holders as of 30 Sep 2024
- Security type / class
- Equity / Common stock, par value $0.0001 per share
- Total 13F shares
- 93,384
- Total 13F value
- $32,071
- Share change
- +71,728
- SEC-reported price per share
- $0.34
- Number of holders
- 7
- Value change
- +$24,614
- Number of buys
- 5
- Number of sells
- 4
- Shares outstanding
- 4,712,245
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2024
Institutions
7
Top holders
7
ENTO full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
GridAI Technologies Corp. SEC filings
GridAI Technologies Corp. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 33749P408
Recent filing periods:
Ownership snapshot
Top reported holders of ENTO - Entero Therapeutics, Inc. - Common stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
David Andrew Hoffman
Disclosed value leader
David Andrew Hoffman
Comparable rows
0/15
Latest evidence
02 Jul 2024
3/4/5
13F
Highest disclosed value: $381,268
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
David Andrew Hoffman has the largest disclosed position value at $381.3K.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens David Andrew Hoffman's linked filing trail.
Disclosed position value
Top 5
David Andrew Hoffman
$381.3K
ARMISTICE CAPITAL, LLC
$155K
Chaitan Khosla PhD
$107.1K
Alastair Riddell
$85K
Mary Theresa Coelho
$85K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| David Andrew Hoffman |
3/4/5
Director
|
—
denominator unverified
|
$381,268
90,778 shares
|
— | 03 Jan 2023 |
| ARMISTICE CAPITAL, LLC |
13F
Company
|
—
denominator unverified
|
$154,993
126,000 shares
|
— | 30 Jun 2024 |
| Chaitan Khosla PhD |
3/4/5
Director
|
—
mixed-class rows
|
$107,127
78,890 shares
mixed-class rows
|
— | 11 Jun 2024 |
| Alastair Riddell |
3/4/5
Director
|
—
denominator unverified
|
$85,008
20,240 shares
|
— | 02 Jan 2024 |
| Mary Theresa Coelho |
3/4/5
Director
|
—
denominator unverified
|
$84,995
20,237 shares
|
— | 02 Jan 2024 |
| Charles J. Casamento |
3/4/5
Director
|
—
denominator unverified
|
$83,735
19,937 shares
|
— | 02 Jan 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
7
Shares
93,384
Rows available
7
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2024 vs Q2 2024 Across Filers
Q2 2024 holders
5
Q3 2024 holders
7
Holder diff
2
| Investor | Q2 2024 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2024 value | Q3 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend